Produced by: Tarun Mishra Designed by: Manoj Kumar
China is facing a significant outbreak of mycoplasma pneumonia, particularly affecting children in both northern and southern provinces. The surge, combined with influenza cases, has raised global concerns despite assurances by Chinese authorities of no novel pathogens.
China reported a surge in respiratory illnesses, with the National Health Commission confirming the first case on November 13. The World Health Organization (WHO) has asked more information from China as hospitalizations among children have surged.
Mycoplasma is a bacterial species that causes mild illnesses in older children and young adults. The infection could escalate to pneumonia, commonly known as 'walking pneumonia.'
Mycoplasma spreads through contact with droplets from infected individuals during coughing and sneezing. Prolonged close contact is believed to be the reason for transmission, often occurring within families, schools, and institutions.
Typical symptoms of mycoplasma infection encompass fever, cough, bronchitis, sore throat, headache, and fatigue. Additionally, infections can result in middle ear problems (otitis media). The duration of symptoms varies, spanning from a few days to more than a month. Symptoms typically occurs two to three weeks after exposure.
Diagnosing mycoplasma infection usually involves assessing observed symptoms and conducting a chest X-ray. In certain instances, blood tests may also be required.
Beijing reported a 40% mycoplasma positivity rate, marking a 1.3-fold increase compared to its 2019 peak. Health data analytics firm Airfinity Ltd. provided insights into the escalating situation, cautioning about the potential impact on the broader population during China's first winter post-COVID-19 restrictions.
To prevent mycoplasma pneumonia, implementing measures to minimise exposure risk is crucial. Practices included good respiratory hygiene, regular hand-washing, and avoiding close contact with infected individuals. Clean and well-ventilated spaces could reduce the likelihood of transmission.
The spike in mycoplasma cases in China is being attributed to potential lingering effects of COVID-19, weakening immune defences. Another explanation reflects an 'immunity debt' resulting from reduced seasonal illnesses during COVID-19 lockdowns, potentially diminishing immunological defences against diseases. India actively monitored the situation to prevent any potential risks.
Union Health Minister Mansukh Mandaviya, in response to the breakout, on Saturday said that the government is monitoring the situation and taking essential measures. The Union Health Ministry reassured India's preparedness for any potential emergency resulting from the evolving influenza situation in China, as reported by Indian Express.